Results 131 to 140 of about 65,128 (311)

TIM-4 Regulates Allergic Airway Inflammation and Mast Cell Activation by Binding to CD300b

Journal of Asthma and Allergy
Yuki Tanabe,1,2 Fumitaka Kamachi,1 Jun Ito,2 Norihiro Harada,2 Sonoko Harada,2,3 Fumihiko Makino,2 Yoshiyuki Abe,4 Nobuhiro Nakano,3 Kumi Izawa,3 Francois Niyonsaba,3 Chiharu Nishiyama,5 Jiro Kitaura,3 Ko Okumura,1,3 Kazuhisa Takahashi,2 Hisaya Akiba,1 ...
Tanabe Y, Kamachi F, Ito J, Harada N, Harada S, Makino F, Abe Y, Nakano N, Izawa K, Niyonsaba F, Nishiyama C, Kitaura J, Okumura K, Takahashi K, Akiba H, Miyake S   +15 more
doaj  

The effect of gender on the prevalence of atopy and asthma [PDF]

, 1993
Joanne Clough
openalex   +1 more source

The association of DNA methylation at birth with adolescent asthma is mediated by atopy [PDF]

, 2023
Aniruddha Rathod, Rajesh Melaram, Hongmei Zhang, Syed Hasan Arshad, Susan Ewart, Meredith Ray, Caroline L. Relton, Wilfried Karmaus, John W. Holloway   +8 more
openalex   +1 more source

Regional variations and temporal trends of atopic diseases in Germany

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Prevalence rates of atopic diseases (atopic dermatitis [AD], allergic asthma [AA], and allergic rhinoconjunctivitis [ARC]) have increased in Germany. However, there is a lack of simultaneous consideration and of precise data on the spatiotemporal variation of these diseases.
Marie Sander, Matthias Augustin, Valerie Andrees, Sandra Hischke, Jobst Augustin   +4 more
wiley   +1 more source

Window-of-opportunity: neonatal gut microbiota and atopy [PDF]

, 2017
Andrew M. Johnson, R. William DePaolo
openalex   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Clinical heterogeneity in vitiligo: Identification of clinical markers based patient clusters

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Vitiligo is a chronic autoimmune disease with heterogeneous clinical presentations. This study analysed 399 patients using hierarchical clustering and identified five phenotypes based on clinical characteristics and lesion distribution. Two groups exhibited high disease activity and extensive involvement.
Laura Galissi, Tristan Benoît, Ribal Merhi, Claire Drullion, Nicolas Andreu, Khaled Ezzedine, Thomas Darde, Katia Boniface, Julien Seneschal   +8 more
wiley   +1 more source

Evaluating the influence of parental atopy on the effectiveness of a maternal dairy-free diet in alleviating infantile colic: a before-and-after study

BMC Pediatrics
Background Infantile Colic (IC) poses a significant challenge for parents as it manifests through repeated and extended episodes of fussiness, crying, or irritability occurring before the age of 5 months. The precise cause of IC is currently unknown. The
Roghaye Ostadi, Ali Pourvali, Amin Tajerian, Saeed Alinezhad, Asghar Lotfi, Javad Javaheri   +5 more
doaj   +1 more source

Global consensus on the management of melanin hyperpigmentation disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A global Delphi consensus of 10 dermatology experts established evidence‐based recommendations for melanin hyperpigmentation disorders, providing unified classification, photoprotection guidance and treatment algorithms. This framework harmonizes terminology and supports individualized management across diverse skin types and health systems.
Thierry Passeron, Seemal R. Desai, Marwa Abdallah, Firas Al‐Niaimi, Ncoza Dlova, Pearl E. Grimes, Jorge Ocampo‐Candiani, Rashmi Sarkar, Leihong Flora Xiang, Helio Amante Miot   +9 more
wiley   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source